Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006733 · ClinicalTrials.gov registry record · Phase 3
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,598
- Enrollment target
NCT01006733 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 1,598 participants.
The verdict
NCT01006733, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,598 participants
- Enrollment target
Study Summary
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention. With this grant, researchers in Missouri, New York, Utah, Illinois, and Texas are developing strategies to improve the safety and effectiveness of clot prevention by customizing a popular blood thinner (warfarin) to each person's genetic and clinical profile. They hypothesize that the use of genetics to guide warfarin therapy will reduce the risk of venous thromboembolism (VTE) postoperatively. They further hypothesize that using a target international normalized ratio (INR) of 1.8 is non-inferior to using a target INR of 2.5 in VTE prevention.
Interventions
- GENETIC Pharmacogenetic
- DRUG Target INR 1.8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,598 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01006733
The ClinicalTrials.gov registry entry for NCT01006733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic is the first listed.
NCT01006733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01006733 about?
NCT01006733 is a clinical study titled "Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT". Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention. With this grant, researchers in Missouri, New York, Utah, Illinois, and Texas are developing strategies to improve...
What is the current status of trial NCT01006733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,598 participants. The study started on 2011-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01006733?
The interventions under investigation include: Pharmacogenetic (GENETIC), Target INR 1.8 (DRUG).
Who is sponsoring clinical trial NCT01006733?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.